Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 2/20 | 0.38 |
| ▸ | GJB2 | P29033 | 5/20 | 0.38 |
| ▸ | GJA1 | P17302 | 3/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.36 |
| ▸ | FGF2 | P09038 | 1/20 | 0.36 |
| ▸ | MDK | P21741 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24059832 | 1.00 | LGALS3 (0.38) | LGALS3GJB2GJA1PTPN1SSTR4 | |
| SCHEMBL18412656 | 0.91 | LGALS3 (0.37) | LGALS3GJB2GJA1PTPN1SSTR4 | |
| SCHEMBL18412646 | 0.88 | PTPN1 (0.36) | LGALS3GJB2PTPN1SSTR4FGF2 | |
| SCHEMBL22013737 | 0.88 | FGF2 (0.43) | LGALS3GJB2PTPN1FGF2MDK | |
| SCHEMBL18412655 | 0.83 | FGF2 (0.36) | LGALS3GJB2PTPN1SSTR4FGF2 | |
| SCHEMBL22013736 | 0.79 | NT5E (0.47) | LGALS3GJB2PTPN1SSTR4PTPN2 | |
| SCHEMBL24059833 | 0.79 | NT5E (0.47) | LGALS3GJB2PTPN1SSTR4PTPN2 | |
| SCHEMBL18394464 | 0.79 | NT5E (0.47) | LGALS3GJB2PTPN1SSTR4PTPN2 | |
| SCHEMBL17087719 | 0.78 | FGF2 (0.37) | LGALS3PTPN1FGF2MDKPTPN2 | |
| SCHEMBL18412650 | 0.78 | LGALS3 (0.41) | LGALS3GJB2GJA1PTPN1SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185838-A1 | CARBOHYDRATE LIGANDS THAT BIND TO IGM ANTIBODIES AGAINST MYELIN-ASSOCIATED GLYCOPROTEIN | UNIV BASEL (CH) | 2022-06-16 | — | — | US | disclosed |
| EP-3116887-B1 | CARBOHYDRATE LIGANDS THAT BIND TO IGM ANTIBODIES AGAINST MYELIN-ASSOCIATED GLYCOPROTEIN | UNIV BASEL (CH) | 2021-02-17 | — | — | EP | disclosed |
| US-9994605-B2 | Carbohydrate ligands that bind to IgM antibodies against myelin-associated glycoprotein | UNIVERSITAET BASEL (CH) | 2018-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185838-A1 | CARBOHYDRATE LIGANDS THAT BIND TO IGM ANTIBODIES AGAINST MYELIN-ASSOCIATED GLYCOPROTEIN | MAG, PMP22, SIGLEC7 | LGALS3 84/4885GJB2 991/4885GJA1 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.